Bristol-Myers Squibb Zerit
Executive Summary
Would provide a one-month cycle of drug free to patients enrolled in the firm's parallel track study if the drug is approved. About 14,000 patients have been treated in the parallel track program to date, but the actual number enrolled at any one time varies ("The Pink Sheet" May 30, T&G-7)